title: Effects of paeoniflorin on the cerebral infarction, behavioral and cognitive impairments at the chronic stage of transient middle cerebral artery occlusion in rats.
abstract: In the present study, the effects of paeoniflorin (PF), a characteristic monoterpene glucoside isolated from Paeoniae Radix, on cerebral infarction, neurological symptoms, tongue protrusion (TP) and performance in the water maze were examined at the chronic stage (4 weeks) of transient cerebral ischemia using a rat middle cerebral artery occlusion (MCAO) model. One-day (10 mg/kg, twice, s.c.) or seven-day (2.5-10 mg/kg, twice a day, s.c.) injection of PF significantly reduced the infarct volume as well as ameliorated the deficits in neurological symptoms caused by transient MCAO at chronic stage. Transient MCAO also induced impairments in TP and performance in the water maze. Treatment with PF was able to reverse or alleviate these impairments. These results indicate that PF may be effective for treatment of stroke.
authors.affiliation: Department of Pharmacology, Shanghai Institute of Materia Medica, SIBS, Chinese Academy of Sciences, 555 Zu-Chong-Zhi Road, Zhangjiang, Shanghai 201203, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Xiao
authors.forename: Ya-Zhou
authors.initials: YZ
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Xue-Ting
authors.initials: XT
authors.lastname: Luo
authors.forename: Yang
authors.initials: Y
authors.lastname: Ye
authors.forename: Xing-Zu
authors.initials: XZ
authors.lastname: Zhu
mesh_terms: D000818:Animals; D001157:Arterial Occlusive Diseases; D001522:Behavior, Animal / Q000187:drug effects*; D001565:Benzoates / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005960:Glucosides / Q000627:therapeutic use*; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D039821:Monoterpenes; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D029596:Paeonia / Q000737:chemistry*; D010936:Plant Extracts / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function; D013550:Swimming; D006027:Glycosides
chemical_list: D001565:Benzoates; D001952:Bridged-Ring Compounds; D005960:Glucosides; D039821:Monoterpenes; D018696:Neuroprotective Agents; D010936:Plant Extracts; C015423:peoniflorin; D006027:Glycosides